The behavior of migraine in patients with Parkinson’s disease

Celmir de Oliveira Vilaça,1 Marco Antonio Araujo Leite,1 Jano Alves de Souza,2 Marco Orsini,1,3 João Santos Pereira,4 Clayton Amaral1,2
1Division of Neurology, Movement Disorders Unit, and 2Headache Research Sector, Antônio Pedro University Hospital, Fluminense Federal University, Niterói; 3Severo Sombra University Center, Medicine Department, Vassouras, Rio de Janeiro; 4Movement Disorders Section, Neurology Service, State University of Rio de Janeiro, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil

Abstract

Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic systems in the central nervous system. In migraine it is supposed to occur hyperactivation of central dopaminergic pathways. We verified the hypothesis of improved migraine in patients who manifest PD. We evaluated 109 patients with PD over 40 years (57 men and 52 women) about the presence throughout the life of migraine, as well as the possibility of improvement in migraine after the onset of motor symptoms of PD. This group was compared to a control group of 152 people (41 men and 152 women) without PD regarding the presence of migraine and its improvement. Twenty-one patients manifested migraine in the group with PD (16 women and 5 men) in which 13 reported improvement in migraine after the onset of symptoms of PD. Among the controls, 37 interviewed had migraine history (32 women and 5 men) among which 20 showed improvement. There was no significant difference when comparing the two groups ($\chi^2_{2,0.05}=0.337; \ P<0.382$). We were unable to relate the improvement of migraine with the emergence of PD motor signs, despite the degeneration of dopaminergic pathways of the central nervous system.

Introduction

The migraine is among the most frequent diseases at a neurology clinic. In Brazil it is estimated its prevalence of 15 to 20% of population. It is characterized by recurrent episodes of headache, in most cases, but not exclusively, of pulsatile characteristic, hemi or holocranial, associated with nausea, vomiting, photophobia and phonophobia, hindering the daily activities of an individual. The crisis lasts 4-72 hours if untreated or ineffectively medicated. The diagnosis of migraine is made on clinical basis using the criteria of the international classification of headaches.

Dopamine (DA) is a neurotransmitter with activity in both the CNS and in PNS (peripheral nervous system). In the human brain dopamine acts as a neurotransmitter in areas related to behavior, memory, milk production, modulation response to painful stimuli and harmonization of movements. The DA derives from the amino acid tyrosine and its synthesis begins with the conversion of phenylalanine into tyrosine by phenylalanine hydroxylase. Tyrosine is then transformed into L-DOPA by tyrosine hydroxylase (TH), which is the primary reaction that controls the velocity of formation of DA. The final reaction consists of the conversion of L-DOPA into dopamine by L-DOPA decarboxylase. Five dopamine receptors are recognized in the CNS, divided into two groups whose numbers represent the order in which they were discovered: D1(D1 e D5) e D2 (D2s, D3, D4).8

PD is characterized by the degeneration of dopaminergic pathways in the CNS, especially the nigrostriatal pathway. The symptoms occur when there is degeneration of 60 to 70% of dopaminergic neurons of this pathway.9 Thereafter, with the progression of disease, other symptoms such as mood disorders, behavior and even dementia clinical conditions, possibly relate to the degeneration of dopaminergic pathways in other segments of the CNS.10

Among the theories on the pathophysiology of migraine, it is suggested the occurrence of hyperactivation of central and peripheral dopaminergic pathways. This hyperactivation causes prodromal symptoms of crises, such as behavioral changes, appetite, yawning, drowsiness and symptoms of the crisis, such as nausea, vomiting or headache through the trigeminal activation. More rarely, the dopaminergic hyperactivation can cause episodes of hypotension or syncope. The DA is involved in migraine mechanisms in many ways.

There is the trigger migraine attack in individuals with migraine headaches, when they use dopamine agonists such as apomorphine, piribedil and the bromocriptine at doses that do not affect healthy controls.11 Confirming this hypothesis, it is observed the efficacy of DA antagonists in the control of migraine crisis.12 In fact, the DA seems to be involved in migraine at different stages and in different ways: prodrome (changes in behavior and yawning);13 activation and pain circuitry awareness (dopamine receptors in the trigeminal sensory nucleus).14

Receptor mutations or enzyme linked to the DA metabolism are associated with higher incidence of migraine. Among these we may mention mutations in D2 receptors and COMT (C-O-methyl transferase).15,16 Changes in the metabolism of DA, starting at tyrosine, diverting it from the hydroxylation pathway to the decarboxylation pathway can lead to increased production of false neurotransmitters such as octopamine, tyramine and synephrine and these can act through painful modulation during crisis in certain brain areas such as the amygdala and hypothalamus.17

In the brainstem the hyperactivity of DA receptors (D2, D3 and D4) in the dorsal nucleus of the vagus and bulbar postrema area are related to nausea and vomiting during crises.2

The syncope, sometimes caused by acute

[page 66]
migraine, seems to be due to the dopaminergic dysfunction of the midbrain substantia nigra and ventral tegmental area of the midbrain and its control over the brain microcirculation, causing vasodilatation and cerebral hyperperfusion through D1 receptors during a crisis.\textsuperscript{18}

In addition, in the peripheral nervous system, hypereexcitation of dopaminergic receptors occurs located in the pre-ganglionic sympathetic nerve endings. This leads to decreased release of noradrenaline (NA) leading to hypotension and it may also cause syncope during an episode of migraine.\textsuperscript{11}

Thus, it is hypothesized that individuals with a previous history of migraine show improvement during the rise of PD.\textsuperscript{19,20}

### Results

Among the 109 patients with PD (mean age 65 years with a minimum of 41 and maximum of 82 years), 35 had recurrent headache history in any period of life and among these, 21 (19\%) had a history of migraine. Among the 152 controls (mean age of 61 years with a minimum of 40 and maximum of 87 years), 58 had a history of headache, of which 37 (24\%) had history of migraine. When comparing the two groups, the differences in the past existence of migraine were not statistically significant (P<0.206) (Table 1).

When comparing patients with migraine in the groups, we observed that among the 21 patients with migraine in the PD group, 13 of these (62\%) reported improvement of PD after the onset of motor symptoms of PD (7 women and 4 men), while 8 (38 \%) showed no improvement (six women and one man). Among the controls, 37 patients manifested migraine (32 women and 5 men) among which 20 subjects (54\%) noticed improved migraine attacks with senescence (19 women and one man), with no improvement in 17 subjects (46\%) (13 women and 4 men). These data did not attribute significant difference in improvement of migraine among patients in the parkinsonian group compared to controls (P<0.382) (Table 2).

We also performed the analysis of cases of migraine improvement of all subjects in both groups (58) when divided by age extremes. We consider three groups, as follows.

Group 1: ages ranging from 40-50 years.
Group 2: ages ranging from 50-60 years.
Group 3: age over 70 years.

When compared, in group 1 there were 10

| Table 1. Comparison between the cases of migraine groups. |
|-----------------------------------------------------------|
| **CG group**                  | **PG group**                      | **Total** |
|-----------------------------|-------------------------------|-----------|
| No                          | 115 (76\%)                     | 88 (81\%) | 203 |
| Migraine                    | **Yes**                       | **No**    | **Left** |
| **Yes**                     | 37 (24\%)                      | 115 (76\%)| 152 |
| **No**                      | 152                           | 88 (81\%) | 240 |

\(\alpha=0.05\).

Table 2. Comparative of migraine improvement between groups.

| **CG group** | **PG group** | **Total** |
|--------------|--------------|-----------|
| Improvement  |              |           |
| **Yes**      | 20 (54\%)    | 13 (62\%) | 33 |
| **No**       | 17 (46\%)    | 8 (38\%)  | 25 |
| Total        | 37           | 21        | 58 |

\(\alpha=0.05\).

Figure 1. Improvement of migraine: comparison between age groups.
cases of migraine in which 7 patients improved and 3 patients showed no improvement regardless of belonging to the control group or PD. In group 3 there were 12 patients with migraine of which 10 showed improvement. This difference gave significant improvement of migraine in older subjects (Group 3) when compared to the younger group (Group 1) (P<0.017) (Figure 1).

Discussion

Our work has the advantage of being the first to address the correlation between PD and migraine using the second international classification of headache 2004. The difference between our results and those obtained previously, is that, the lack of improvement of migraine in patients with PD can relate to the difference of migraine diagnostic criteria or the different methods in the selection or exclusion of samples. Although a difference between groups of statistical value does not occur, we question whether the difference of 8% (54% versus 46%) obtained, presents clinical importance. We expected, for example, a higher prevalence of other types of headaches than the PD in the parkinsonians, for these encompass the tension-type headache, the most prevalent in the population. However, we believe that the type of sample, obtained at a tertiary hospital, where migraine is the most prevalent primary headache, has been partly responsible for these results. The fact that the tension-type headache characterized by pain from weak to moderate intensity, which does not disturb the activities of daily living, would lead to recall bias, decreasing its prevalence in our study.

About the limitations of the work performed, we admit that the question of improvement of migraine in groups during the questionnaire application has a high degree of subjectivity and is subject to recall bias. However, we found no validated tools that could provide more reliable data to the research objective of evaluating the behavior of migraine in patients with PD. We believe that the study has minimized most of the factors responsible for recall bias, since it used a questionnaire based on the classification of headache and evaluated a disease as a chronic course and with crises often disabling as migraine, reducing the factors like time and exposure and significance of events such as factors to recall bias.

Although in our sample there were individuals with PD dementia, we do not use tools that would allow exclusion of patients with dysfunction of a single cognitive domain. Thus, we cannot rule out the involvement of other different cognitive mnemonic functions, such as attention deficit, which could interfere in the questionnaire responses.

The results of our study indicate that senescence, rather than the presence or absence of PD is related to the improvement of migraine. This may be related to decreased dopamine sensitivity with aging. This fact does not occur with serotonergic system. However we must emphasize that due to the sample size we did not realize the impact assessment of senescence in migraine in each group separately. This fact makes it impossible to rule out the senescence by presenting different impacts in controls and in patients with PD.

Finally, as almost all the studies involving patients with PD, this took into consideration only patients after the onset of motor symptoms of the disease, this as the nucleus of the solitary tract and motor of the vagus. We theorize the possibility of the occurrence of changes in the behavior of migraine in previous stages to the emergence of motor symptoms. For example, the -synuclein accumulation in these topographies would cause changes in vegetative symptoms of migraine crisis as nausea and vomiting. The osmophobia that triggers or accompanying migraine crisis could be modified by olfactory alterations that occurs in patients with PD long before the onset of motor symptoms when synucleinopathy has already affected these pathways. The same would happen with photophobia as a symptom of migraine, that occurs degeneration in retino-thalamic dopaminergic pathways. This fact would decrease the action of light stimuli as an activator of thalamic pathways linked to trigeminovascular activation during a crisis and allodynia of migraine.

Conclusions

Our work has not confirmed that Parkinson’s disease is an attenuator factor of migraine attacks. The improvement of migraine in patients with PD may be related to senescence, regardless of the presence of PD. Further work involving the relationship between migraine and PD is necessary taking into consideration the already established dopaminergic alterations in both diseases.

References

1. Queiroz LP, Peres MFP, Piovesan EJ, et al. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009;29: 642-9.
2. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24:1-160.
3. Nutt J, Wooten G. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 2005;352:1-7.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
5. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006;21:800-8.
6. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30:194-202.
7. Akerman S, Goadsby P, Currents H. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007;27: 1308-14.
8. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004;108:17-40.
9. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339: 1044-53.
10. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
11. Peroutka SJ. Dopamine and migraine. Neurology 1997;49:650-6.
12. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14:27-35.
13. Palmas MA, Cherchi A, Stochino E, et al. Dopamine genes and migraine. J Headache Pain 2000;1:513-6.
14. Charbit AR, Akerman S, Goadsby PJ. Dopamine: what’s new in migraine? Curr Opin Neurol 2010;23:275-81.
15. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco I alleles. Neurology 1997;49: 201-6.
16. Erdal ME, Herken H, Yilmaz M, Bayazit YA. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res 2001;94:193-6.
17. D’Andrea G, D’Arrigo A, Dalle Carbonare M, Leon A. Pathogenesis of migraine: role of neuromodulators. Headache 2012;52: 1155-63.
18. Krimer LS, Muly EC, Williams GV, et al. Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1998;1: 286-9.
19. Barbanti P, Fabbri G, Vanacore N, et al. Dopamine and migraine: does Parkinson’s...
20. Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg 1992;94:168-70.

21. Sahler K. Epidemiology and cultural differences in tension-type headache. Curr Pain Headache Rep 2012;16:525-32.

22. Jensen R. Diagnosis, epidemiology, and impact of tension-type headache. Curr Pain Headache Rep 2003;7:455-9.

23. Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87-91.

24. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis 2012;46:590-6.

25. Dujardin K, Tard C, Duhamel A, et al. The pattern of attentional deficits in Parkinson's disease. Parkinsonism Relat Disord 2013;19:300-5.

26. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.

27. Cao Y, Aurora SK, Nagesh V, et al. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 2002;59:72-8.

28. Cave J, Baker H. Dopamine systems in the forebrain. Adv Exp Med Biol 2009;651:15-35.

29. Huisman E, Uylings HBM, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 2004;19:687-92.

30. Kagan R, Kainz V, Burstein R, et al. Hypothalamic and basal ganglia projections to the posterior thalamus: Possible role in modulation of migraine headache and photophobia. Neuroscience 2013;248C:359-68.